Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Ludwig, H; Cortelezzi, A; Van Camp, BG; Polli, E; Scheithauer, W; Kuzmits, R; Linkesch, W; Gisslinger, H; Sinzinger, H; Fritz, E.
Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.
Oncology. 1985; 42 Suppl 1(3):19-25
Doi: 10.1159/000226080
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Forty-two patients with multiple myeloma were allocated to two groups to receive either polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone, or recombinant interferon-alpha 2C monotherapy. The response rate of 43% in the interferon group was significantly lower than that in the chemotherapy group (89%). Patients with stage I disease showed better response rates than those with stage II or stage III disease. Eleven patients with thrombocythaemia due to polycythaemia vera, chronic myeloid leukaemia or essential thrombocythaemia were treated with recombinant interferon-alpha 2C and complete remissions were achieved in 7 of the 8 evaluable patients. Side-effects were common on interferon therapy, but could be reduced by dose reduction and were reversed by cessation of treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Female - therapeutic use
- Humans - therapeutic use
- Interferon Type I - adverse effects
- Male - adverse effects
- Middle Aged - adverse effects
- Multiple Myeloma - drug therapy
- Myeloproliferative Disorders - complications
- Platelet Count - complications
- Recombinant Proteins - adverse effects
- Thrombocythemia, Hemorrhagic - complications